Lower BCL11B expression is associated with adverse clinical outcome for patients with myelodysplastic syndrome.
Ontology highlight
ABSTRACT: Myelodysplastic syndrome (MDS) is an aggressive and genetically heterogeneous disease with poor prognosis. Cellular immune disorder is a common characteristic of this disease and is thought to be related to clinical outcome. Alterations in T cell clonal expansion and T cell dysfunction has been detected in MDS patients. Little is known about whether there are immune biomarkers to evaluate the T cell alterations with clinical outcome. Previous studies have demonstrated that B-cell leukemia/lymphoma 11B (BCL11B) plays an important role in regulating T cell development and proliferation. In this study, the prognostic value of BCL11B for MDS patients was explored by analyzing RNA-seq data from 270 patients in two datasets in the Gene Expression Omnibus (GEO) database and real-time quantitative
SUBMITTER: Huang X
PROVIDER: S-EPMC8193904 | biostudies-literature | 2021 Jun
REPOSITORIES: biostudies-literature
ACCESS DATA